interleukin-2 + lymphotactin + allogeneic neuroblastoma cells

This investigational cancer vaccine consists of allogeneic neuroblastoma cells that have been genetically modified to secrete the cytokine interleukin-2 (IL-2) and the C-type chemokine lymphotactin (Lptn). The therapeutic rationale is based on a multi-step immune activation: lymphotactin acts as a chemoattractant to recruit T-lymphocytes and natural killer (NK) cells to the vaccination site, while the local secretion of IL-2 promotes the activation and proliferation of these recruited effector cells. By using allogeneic neuroblastoma cells as the substrate, the vaccine presents a broad spectrum of tumor-associated antigens to the primed immune system, potentially inducing a systemic and durable anti-tumor response. This approach was primarily developed and evaluated in clinical trials for high-risk neuroblastoma, aiming to overcome the typically low immunogenicity of these tumors.

Other names

IL-2/Lptn-modified neuroblastoma vaccineinterleukin-2 and lymphotactin gene-modified allogeneic neuroblastoma cellsinterleukin2 and lymphotactin gene-modified allogeneic neuroblastoma cellsinterleukin 2 and lymphotactin gene-modified allogeneic neuroblastoma cellsallogeneic neuroblastoma cells transduced with interleukin-2 and lymphotactin